Kura Oncology (KURA) Competitors $6.50 +0.02 (+0.23%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KURA vs. SDGR, DNLI, MIRM, TARS, GMTX, BEAM, NAMS, KYMR, BLTE, and BHCShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Schrödinger (SDGR), Denali Therapeutics (DNLI), Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Beam Therapeutics (BEAM), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Belite Bio (BLTE), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Schrödinger Denali Therapeutics Mirum Pharmaceuticals Tarsus Pharmaceuticals Gemini Therapeutics Beam Therapeutics NewAmsterdam Pharma Kymera Therapeutics Belite Bio Bausch Health Companies Kura Oncology (NASDAQ:KURA) and Schrödinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends. Do analysts rate KURA or SDGR? Kura Oncology presently has a consensus target price of $23.89, suggesting a potential upside of 269.23%. Schrödinger has a consensus target price of $32.80, suggesting a potential upside of 27.95%. Given Kura Oncology's higher probable upside, equities research analysts plainly believe Kura Oncology is more favorable than Schrödinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92Schrödinger 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is KURA or SDGR more profitable? Kura Oncology has a net margin of 0.00% compared to Schrödinger's net margin of -91.84%. Schrödinger's return on equity of -35.77% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -44.09% -39.57% Schrödinger -91.84%-35.77%-24.51% Which has stronger earnings & valuation, KURA or SDGR? Schrödinger has higher revenue and earnings than Kura Oncology. Schrödinger is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$53.88M9.70-$152.63M-$2.03-3.19Schrödinger$207.54M9.02$40.72M-$2.57-9.97 Which has more volatility & risk, KURA or SDGR? Kura Oncology has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Does the media refer more to KURA or SDGR? In the previous week, Kura Oncology had 14 more articles in the media than Schrödinger. MarketBeat recorded 20 mentions for Kura Oncology and 6 mentions for Schrödinger. Schrödinger's average media sentiment score of 1.18 beat Kura Oncology's score of 0.59 indicating that Schrödinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrödinger 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in KURA or SDGR? 79.1% of Schrödinger shares are held by institutional investors. 6.4% of Kura Oncology shares are held by company insiders. Comparatively, 8.6% of Schrödinger shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in KURA or SDGR? Kura Oncology received 383 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 69.79% of users gave Kura Oncology an outperform vote while only 58.33% of users gave Schrödinger an outperform vote. CompanyUnderperformOutperformKura OncologyOutperform Votes43969.79% Underperform Votes19030.21% SchrödingerOutperform Votes5658.33% Underperform Votes4041.67% SummaryKura Oncology beats Schrödinger on 10 of the 19 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$522.63M$6.83B$5.54B$8.06BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-2.747.4622.7418.82Price / Sales9.70259.70406.04107.26Price / CashN/A65.8538.1834.62Price / Book1.216.616.804.35Net Income-$152.63M$143.37M$3.22B$247.85M7 Day Performance0.62%3.56%2.24%2.83%1 Month Performance-0.77%5.90%3.58%4.32%1 Year Performance-68.58%-2.45%16.74%5.96% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology4.1274 of 5 stars$6.51+0.2%$23.89+267.2%-68.0%$525.46M$53.88M-2.76130Earnings ReportAnalyst ForecastNews CoverageGap DownSDGRSchrödinger2.4957 of 5 stars$26.19+1.7%$33.00+26.0%-1.5%$1.91B$207.54M-11.19790Upcoming EarningsPositive NewsGap UpDNLIDenali Therapeutics4.1722 of 5 stars$13.15+3.2%$37.57+185.7%-0.6%$1.91B$330.53M-4.76430Upcoming EarningsPositive NewsGap UpMIRMMirum Pharmaceuticals4.2659 of 5 stars$38.39-1.8%$58.20+51.6%+68.8%$1.90B$336.89M-19.00140Upcoming EarningsPositive NewsTARSTarsus Pharmaceuticals2.0784 of 5 stars$48.51-1.5%$63.67+31.2%+54.8%$1.86B$182.95M-12.7350Earnings ReportUpcoming EarningsAnalyst ForecastNews CoveragePositive NewsGMTXGemini TherapeuticsN/A$42.17+2.8%N/A+73.2%$1.83BN/A-42.1730BEAMBeam Therapeutics3.0939 of 5 stars$18.24+7.3%$49.45+171.1%-8.8%$1.82B$63.52M-10.36510Upcoming EarningsShort Interest ↑News CoverageHigh Trading VolumeNAMSNewAmsterdam Pharma3.1671 of 5 stars$16.26-0.5%$43.33+166.5%-8.8%$1.79B$45.56M-6.254Positive NewsKYMRKymera Therapeutics2.0327 of 5 stars$27.16+4.6%$56.36+107.5%-4.7%$1.76B$47.07M-11.61170Upcoming EarningsNews CoveragePositive NewsBLTEBelite Bio2.9922 of 5 stars$54.69-3.0%$96.67+76.8%+50.9%$1.74BN/A-49.2710News CoveragePositive NewsBHCBausch Health Companies4.1886 of 5 stars$4.72-7.5%$7.17+51.8%-39.5%$1.74B$9.63B-39.3319,900Analyst Upgrade Related Companies and Tools Related Companies SDGR Alternatives DNLI Alternatives MIRM Alternatives TARS Alternatives GMTX Alternatives BEAM Alternatives NAMS Alternatives KYMR Alternatives BLTE Alternatives BHC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KURA Stock Free KURA Stock Alerts